EichorEICHOR
Condition: Triple Negative Metastatic Breast Cancer Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: Triple Negative Metastatic Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of XB010 in Subjects With Solid Tumors
Phase 1 · 20 location(s) · Exelixis · NCT06545331A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerabili
Phase 1/Phase 2 · 10 location(s) · Lumara Bio Oncologics GmbH · NCT05706129Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Pa
Phase 2 · 1 location(s) · The Netherlands Cancer Institute · NCT04159818Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients
Phase 2 · 5 location(s) · European Institute of Oncology · NCT06690840A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negati
Phase 2 · 1 location(s) · University of Washington · NCT07078604Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
Phase 1 · 1 location(s) · Novartis Pharmaceuticals · NCT07630961Saci Nivo Rela for TNBC
Phase 1/Phase 2 · 1 location(s) · Yale University · NCT06963905A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Hi
Phase 1/Phase 2 · 3 location(s) · University of Southern California · NCT04333706All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Nega
Phase 2 · 2 location(s) · Fudan University · NCT06636981A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT06732323A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT06246968A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple N
Phase 1 · 1 location(s) · University of Southern California · NCT05989828Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Phase N/A · 3 location(s) · Mayo Clinic · NCT06349642Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
NA · 1 location(s) · Brigham and Women's Hospital · NCT04030507A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast
Phase 2 · 12 location(s) · Memorial Sloan Kettering Cancer Center · NCT06099769JS207 Combination Therapy in Triple-negative Breast Cancer
Phase 2 · 22 location(s) · Shanghai Junshi Bioscience Co., Ltd. · NCT07045311Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07486089A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 · 12 location(s) · Pliant Therapeutics, Inc. · NCT06270706A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifan
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT06959537ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
Phase 2 · 1 location(s) · Laura Huppert, MD, BA · NCT06224673SMP-3124LP in Adults With Advanced Solid Tumors
Phase 1/Phase 2 · 11 location(s) · Sumitomo Pharma America, Inc. · NCT06526819MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Phase 1 · 2 location(s) · Memgen, Inc. · NCT05076760Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast
Phase 3 · 7 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06889688Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followe
Phase 2 · 6 location(s) · IFOM ETS - The AIRC Institute of Molecular Oncology · NCT05582538A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients Wit
Phase 1/Phase 2 · 1 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT06508216DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Phase 2 · 3 location(s) · Nancy Lin, MD · NCT06176261Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
Phase 3 · 1 location(s) · Fudan University · NCT05806060Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
Phase N/A · 1 location(s) · University of California, San Francisco · NCT06774027First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Incl
Phase 1 · 6 location(s) · Accent Therapeutics · NCT06799065Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metas
Phase 2 · 30 location(s) · National Cancer Institute (NCI) · NCT03606967
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.